Your browser doesn't support javascript.
loading
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.
Nissink, J Willem M; Bazzaz, Sana; Blackett, Carolyn; Clark, Matthew A; Collingwood, Olga; Disch, Jeremy S; Gikunju, Diana; Goldberg, Kristin; Guilinger, John P; Hardaker, Elizabeth; Hennessy, Edward J; Jetson, Rachael; Keefe, Anthony D; McCoull, William; McMurray, Lindsay; Olszewski, Allison; Overman, Ross; Pflug, Alexander; Preston, Marian; Rawlins, Philip B; Rivers, Emma; Schimpl, Marianne; Smith, Paul; Truman, Caroline; Underwood, Elizabeth; Warwicker, Juli; Winter-Holt, Jon; Woodcock, Simon; Zhang, Ying.
Afiliación
  • Nissink JWM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Bazzaz S; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • Blackett C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Clark MA; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • Collingwood O; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Disch JS; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • Gikunju D; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • Goldberg K; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Guilinger JP; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • Hardaker E; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Hennessy EJ; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Jetson R; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • Keefe AD; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • McCoull W; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • McMurray L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Olszewski A; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
  • Overman R; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Pflug A; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Preston M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Rawlins PB; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Rivers E; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Schimpl M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Smith P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Truman C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Underwood E; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Warwicker J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Winter-Holt J; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Woodcock S; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Zhang Y; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
J Med Chem ; 64(6): 3165-3184, 2021 03 25.
Article en En | MEDLINE | ID: mdl-33683117
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Tirosina Quinasa c-Mer Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Tirosina Quinasa c-Mer Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos